Diabetes Medications With Cardiovascular Protection After HARMONY Outcomes and DECLARE-TIMI 58: Could Metformin, Pioglitazone, SGLT2 Inhibitors and Long-Acting GLP-1 Receptor Agonists Complement Each Other to Save Lives by Different Mechanisms?

British Journal of Diabetes
doi 10.15277/bjd.2019.207
Full Text
Abstract

Available in full text

Date
Authors
Publisher

ABCD Diabetes Care, Ltd.

Related search

SGLT2 Inhibitors or GLP-1 Receptor Agonists as Second-Line Therapy in Type 2 Diabetes: Patient Selection and Perspectives

Vascular Health and Risk Management
2016English

The Cardiovascular Effects of GLP-1 Receptor Agonists

Cardiovascular Therapeutics
MedicineCardiovascular MedicinePharmacologyCardiology
2010English

Cardiovascular Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2014English

Role and Development of GLP-1 Receptor Agonists in the Management of Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2009English

DECLARE-TIMI 58 Trial in the Context of EMPA-REG OUTCOME and CANVAS

Diabetes Mellitus
Internal MedicineEndocrinologyMetabolismDiabetes
2020English

Mechanisms of Action of Metformin With Special Reference to Cardiovascular Protection

Diabetes/Metabolism Research and Reviews
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Could Drug Consumption Rooms Save Lives?

British Medical Journal
Medicine
2019English

Discovery of Novel and Long Acting GLP-1 Analogs

2015English

How the Next Recession Could Save Lives

Nature
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy